RYCFX Mutual Fund

NAV$46.85

Fund Essentials - as of Mar 31, 2026

Net Assets
$373,196.54
Expense Ratio
2.38%
Dividend Yield (Current)
20.31%
Holdings
75
Inception Date
Mar 30, 2001
Fund Family
Rydex Funds
Investment Style
••••••••••
Asset Class
••••••••••
Legal Structure
••••••••••
Dividend Frequency
Annually

Performance

YTD+7.03%
1 Year+72.70%
3 Year+27.50%
5 Year+11.94%
10 Year+11.10%

Asset Allocation

Stocks: 99.55%
Bonds: 0.44%

Top Holdings

View All →
TickerNameWeight
ABBVAbbvie Inc7.39%
AMGNAmgen Inc.5.23%
GILDGilead Sciences Inc4.96%
VRTXNvaesrtex Pharmaceuticals Inc4.01%
REGNRegeneron Pharmaceuticals, Inc.3.56%
Top 10 Concentration: 36.65%Report Date: Mar 31, 2026
Download all 75 holdings for RYCFX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Dividend Yield (Current)
20.31%
Frequency
Annually
Latest Distribution
$15.77
-

Peer Comparison

Benchmark
••••••••••
Outperforming by ••••%
Ranked #••• of •,••• funds
This Mutual Fund
+••.••%
Peer Avg
+••.••%
Premium Feature
Sign in to unlock peer comparison, category rankings and more

RYCFX Mutual Fund Overview

RYCFX Mutual Fund (Rydex Biotechnology Fund Class C) is managed by Rydex Funds with $373,196.54 in net assets. RYCFX expense ratio is 2.38%, holding 75 positions across sectors including Health Care, Unknown, Other. Inception date: 2001-03-30.

RYCFX performance shows a YTD return of 7.03%. The 1-year return is 72.70% and the 5-year return is 11.94%. RYCFX dividend yield stands at 20.31%, paid annually.

RYCFX top holdings include Abbvie Inc (7.4%), Amgen Inc. (5.2%), Gilead Sciences Inc (5.0%), Nvaesrtex Pharmaceuticals Inc (4.0%), Regeneron Pharmaceuticals, Inc. (3.6%). View all RYCFX holdings, sector breakdown, or dividend history.

RYCFX can be compared against other funds using the overlap calculator or side-by-side comparison tool. RYCFX alternatives are available via the screener, along with tax-loss harvesting opportunities.